Mostrar el registro sencillo del ítem

dc.contributor.authorBenabdellah, Karim
dc.contributor.authorSánchez Hernández, Sabina
dc.contributor.authorAguilar González, Araceli 
dc.contributor.authorMaldonado Pérez, Noelia 
dc.contributor.authorCortijo Gutierrez, Marina
dc.contributor.authorRamos Hernández, Iris
dc.contributor.authorTristán Manzano, María 
dc.contributor.authorMartín, Francisco
dc.date.accessioned2020-06-24T11:49:03Z
dc.date.available2020-06-24T11:49:03Z
dc.date.issued2020
dc.identifier.citationBenabdellah, K., Sánchez‐Hernández, S., Aguilar‐González, A., Maldonado‐Pérez, N., Gutierrez‐Guerrero, A., Cortijo‐Gutierrez, M., ... & Martin, F. (2020). Genome‐edited adult stem cells: Next‐generation advanced therapy medicinal products. Stem Cells Translational Medicine, 9(6), 674-685. [Doi: 10.1002/sctm.19-0338]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/62706
dc.description.abstractOver recent decades, gene therapy, which has enabled the treatment of several incurable diseases, has undergone a veritable revolution. Cell therapy has also seen major advances in the treatment of various diseases, particularly through the use of adult stem cells (ASCs). The combination of gene and cell therapy (GCT) has opened up new opportunities to improve advanced therapy medicinal products for the treatment of several diseases. Despite the considerable potential of GCT, the use of retroviral vectors has major limitations with regard to oncogene transactivation and the lack of physiological expression. Recently, gene therapists have focused on genome editing (GE) technologies as an alternative strategy. In this review, we discuss the potential benefits of using GE technologies to improve GCT approaches based on ASCs. We will begin with a brief summary of different GE platforms and techniques and will then focus on key therapeutic approaches that have been successfully used to treat diseases in animal models. Finally, we discuss whether ASC GE could become a real alternative to retroviral vectors in a GCT setting.es_ES
dc.description.sponsorshipEuropean Regional Development Fund (FEDER), Grant/Award Numbers: PI18/01610, PI18/00330, PI18/00337, grants PI12/01097; Spanish ISCIII Health Research Fundes_ES
dc.language.isoenges_ES
dc.publisherWILEYes_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectAdult stem cellses_ES
dc.subjectCRISPRes_ES
dc.subjectElectroporationes_ES
dc.subjectGene delivery systems in vivo or in vitroes_ES
dc.subjectGene therapy es_ES
dc.subjectHematopoietic stem cells (HSCs)es_ES
dc.subjectMesenchymal stem cells (MSCs)es_ES
dc.subjectPluripotent hemopoietic stem cellses_ES
dc.titleGenome-edited adult stem cells: Next-generation advanced therapy medicinal productses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1002/sctm.19-0338


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España